Pharmaceutical company Novartis broke ground on May 7, 2026, on its new 46,000-sq.-ft. radioligand therapy (RLT) manufacturing site in Denton, Texas, which is part of a $23 billion investment in United States manufacturing and research.
The start of construction on the company's first Texas‑based manufacturing facility brings U.S. RLT production closer to patients across the southern U.S., becoming the fifth RLT site nationwide.
A contractor and a dollar amount on this specific project were not mentioned.
"Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale," said Vas Narasimhan, CEO of Novartis. "Breaking ground in Denton further strengthens our U.S. supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them."
This expansion reinforces Novartis' leadership as the first company to deliver RLT at scale, building the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the site is expected to become operational in 2028 and create new U.S.-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities.
U.S. Under Secretary of Commerce for Industry and Security Jeffrey Kessler, Swiss Ambassador to the U.S. Ralf Heckner, Texas state Sen. Brent Hagenbuch, Texas state Rep. Andy Hopper and Denton Mayor Gerard Hudspeth joined Novartis leadership, employees, and community partners to celebrate the start of construction.
The Texas facility bolsters the Novartis coast-to-coast RLT manufacturing network, with existing U.S. sites in New Jersey, Indiana and California, and a new site being added in Florida. The Denton site adds to the largest U.S. RLT manufacturing network.
In April 2025, Novartis committed $23 billion over five years to grow its U.S. research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction — part of the company's broader effort to manufacture all key medicines for U.S. patients in the U.S., supporting supply resilience and dependable delivery of medicines.
